Publicado
Insulina y enfermedad de alzheimer: una diabetes tipo 3?
Insulin and Alzheimer disease: type 3 diabetes?
Palabras clave:
Insulina, enfermedad de alzheimer, resistencia a la insulina. (es)Insulin, Alzheimer disease, insulin resistance (en)
Alzheimer Disease is a neurodegenerative disease of central nervous system whose incidence will increase in next years. Recent investigations relate alzheimer with insulin signaling defects in neurons. Is alzheimer Disease a type 3 diabetes? In this communication write a brief article about evidences from this alzheimer‘s disease model.
Referencias
Plum L, Schubert M, Brüning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab. 2005; 16: 59-65.
Zhao W, Chen H, Xu H, Moore E, Meiri N, Quon MJ, et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem. 1999; 274: 34893-34902.
Xu AW, Kaelin CB, Takeda K, Akira S, Schwartz MW, Barsh GS. PI3K integrates the action of insulin and leptin on hypothalamic neurons. J Clin Invest. 2005; 115: 951-958.
Lee CC, Huang CC, Wu MY, Hsu KS. Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3 kinase-AKT-Mammalian target of rapamycin signaling pathway. J Biol Chem. 2005; 280: 18543-18550.
Van der Heide LP, Ramakers GM, Smidt MP. Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol. 2006; 79 : 205-221.
Banks WA. The source of cerebral insulin. Eur J Pharmacol. 2004; 490 : 5-12.
Janson J, Laedtke T, Parisi JE, O´Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004; 53:474-481.
Vanhanen M, Koivisto K, Kuusisto J, Mykkanen L, Helkala EL, Hanninen T, et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care. 1998; 21: 398-402.
Price DL. Aging of the brain and dementia of the Alzheimer type. En Kandel ER, Schwartz JH, Jessel TM eds. Principles of neural sciences. New York: McGraw-Hill. 2000; 1149-1168.
Frolich L, Blun-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, et al. Brain insulin and insulin receptors in aging and sporadic alzheimer´s disease. J Neural Transm 1998; 105: 423-438.
Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, et al. Insulin metabolism in alzheimer´s disease differs according to Apolipoprotein E genotype and gender. Neuroendocrinology. 1999; 70: 146-152.
Mangone CA. Enfermedad de Alzheimer. En Micheli F, Nogués MA, Asconapé JJ, Fernandez MM, Biller J eds. Tratado de Neurología Clínica: Buenos Aires. 2003; 712-729.
Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer´s Disease. Exp Gerontol. 2007; 42: 10-21.
Craft S. Insulin resistance syndrome and alzheimer´s disease: age-and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005; 26 suppl (1): 65-69.
Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer´s disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 2003; 28 :809-822.
Blomqvist ME, Silburn PA, Buchanan DD, Andreasen N, Blennow K, Pedersen NL, et al. Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics. 2004; 5:115-119.
Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006; 443(7113): 870-874.
Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V,et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000; 20: 1657-1665.
Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging. 2005; 26: 645-654.
Cole G. A transgenic triple scores a home run. Nat Med. 2006; 12: 762-763.
Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, Krone W, et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes. 2005; 54: 3343-3348.
Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci. 2001; 114 (Pt 16):2903-2910.
Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001; 74: 270-280.
Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD,et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry. 1999; 56: 1135-1140.
Wan Q, Xiong ZG, Man HY, Ackerley CA, Braunton J, Lu WY, et al. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature. 1997; 388(6643): 686-690.
Landreth G. PPARgamma agonist as new therapeutic agents for the treatment of Alzheimer´s disease. Exp Neurol. 2006; 199: 245-248.
Visitas a la página del resumen del artículo
Descargas
Cómo citar
Licencia
Derechos de autor 2007 Revista de la Facultad de Medicina
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
-
